摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-methylbut-2-enyl)-2-(3-oxobutyl)-1,3-cyclohexanedione | 1210056-55-5

中文名称
——
中文别名
——
英文名称
2-(3-methylbut-2-enyl)-2-(3-oxobutyl)-1,3-cyclohexanedione
英文别名
2-(3-Methylbut-2-enyl)-2-(3-oxobutyl)cyclohexane-1,3-dione;2-(3-methylbut-2-enyl)-2-(3-oxobutyl)cyclohexane-1,3-dione
2-(3-methylbut-2-enyl)-2-(3-oxobutyl)-1,3-cyclohexanedione化学式
CAS
1210056-55-5
化学式
C15H22O3
mdl
——
分子量
250.338
InChiKey
DQCXZXVRJUCMIL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    51.2
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Asymmetric Synthesis of Wieland–Miescher and Hajos–Parrish Ketones Catalyzed by an Amino-Acid-Derived Chiral Primary Amine
    作者:Pengxin Zhou、Long Zhang、Sanzhong Luo、Jin-Pei Cheng
    DOI:10.1021/jo202433v
    日期:2012.3.2
    efficient and practical protocol for the synthesis of both Wieland–Miescher ketone and Hajos–Parrish ketone as well as their analogues. The reaction can be conducted in gram scale with 1% mol catalyst loading producing high enantioselectivity (up to 96% ee) and excellent yields (up to 98%). This procedure represents one of the most efficient methods for the synthesis of these versatile chiral building blocks
    本文描述了一种简单的手性伯胺催化高效,实用的方案,用于合成Wieland–Miescher酮和Hajos–Parrish酮及其类似物。该反应可以以克为单位进行,催化剂负载量为1%mol,产生高对映选择性(最高96%ee)和极好的收率(最高98%)。该步骤代表了合成这些通用手性结构单元的最有效方法之一。
  • Efficient Solvent-Free Robinson Annulation Protocols for the Highly Enantioselective Synthesis of the Wieland-Miescher Ketone and Analogues
    作者:Ben Bradshaw、Gorka Etxebarría-Jardi、Josep Bonjoch、Santiago F. Viózquez、Gabriela Guillena、Carmen Nájera
    DOI:10.1002/adsc.200900321
    日期:2009.10
    A highly efficient (93% overall yield) and enantioselective (94% ee) synthesis of the Wieland–Miescher ketone (10-g scale) through a solvent-free Robinson annulation procedure is reported. The process involves only 1 mol% triethylamine as the base in the initial Michael process and the organocatalyst N-tosyl-(Sa)-binam-L-prolinamide (2 mol%) and benzoic acid (0.5 mol%) for the intramolecular aldol
    据报道,通过无溶剂的罗宾逊环化方法可以高效地合成Wieland-Miescher酮(10 g规模)(对比例为94%ee)(对映体,产率为94%ee)。该方法在最初的迈克尔方法中仅涉及1摩尔%的三乙胺作为碱,而分子内羟醛的有机催化剂N-甲苯磺酰基- (S a)-比纳姆-L-脯酰胺(2摩尔%)和苯甲酸(0.5摩尔%)过程。该绿色协议适用于Wieland–Miescher酮的多种有价值的构建基类似物(10个示例)。其中,用于萜烯合成的值得注意的化合物是8a-烯丙基衍生物,以93%的收率和97%的ee制备在允许有机催化剂的回收和再利用的过程中。此外,还开发了一种一锅两步工艺。
  • Desymmetrisation of <i>meso</i>-diones promoted by a highly recyclable polymer-supported chiral phosphoric acid catalyst
    作者:Lidia Clot-Almenara、Carles Rodríguez-Escrich、Miquel A. Pericàs
    DOI:10.1039/c7ra13471a
    日期:——
    A polystyrene-supported BINOL-derived chiral phosphoric acid has been applied to the desymmetrisation of meso-diones to produce enantioenriched cyclohexenones. The catalytic resin has proven highly active and robust, giving rise to Hajos–Parrish or Wieland–Miescher type products in good yields and enantioselectivities, while allowing for extended recycling.
    苯乙烯负载的 BINOL 衍生的手性磷酸已被应用于内消旋二酮的去对称化,以生产对映体富集的环己烯酮。该催化树脂已被证明具有高活性和稳定性,能够以良好的收率和对映选择性产生 Hajos-Parrish 或 Wieland-Miescher 型产品,同时允许延长回收期。
  • [EN] PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES<br/>[FR] DÉRIVÉS ÉNONE DE PYRIMIDINE TRICYCLIQUE POUR L'INHIBITION DE RORγ ET D'AUTRES UTILISATIONS
    申请人:REATA PHARMACEUTICALS INC
    公开号:WO2018111315A8
    公开(公告)日:2019-07-11
  • PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES
    申请人:REATA PHARMACEUTICALS, INC.
    公开号:US20200131148A1
    公开(公告)日:2020-04-30
    Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit RORγ and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.
查看更多